Trial Profile

A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hafnium oxide (Primary) ; Carboplatin; Durvalumab; Paclitaxel
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms CONVERGE
Sponsors Johnson & Johnson Innovation

Most Recent Events

17 May 2026 According to a Nanobiotix media release, data from this trial were presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting.
17 May 2026 Results presented in the Nanobiotix media release.
01 Apr 2026 According to a Nanobiotix media release, first results form this trial were presented in Q1 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com